Results 11 to 20 of about 605,792 (294)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World

Frontiers in Endocrinology, 2021
Neuroendocrine tumors overexpress somatostatin receptors, which serve as important and unique therapeutic targets for well-differentiated advanced disease.
Mayank Patel, Isabel Tena, Isabel Tena, Abhishek Jha, David Taieb, Karel Pacak   +5 more
doaj   +2 more sources

18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study

EJNMMI Research, 2018
Background Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, 18F-fluoro-deoxy-glucose (18F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use of 68Ga-somatostatin analogs.
Silvia Taralli, Martina Sollini, Michele Milella, Germano Perotti, Angelina Filice, Massimo Menga, Annibale Versari, Vittoria Rufini   +7 more
doaj   +2 more sources

¹⁸F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use [PDF]

Journal of Nuclear Medicine, 2023
Molecular imaging of the somatostatin receptor plays a key role in the clinical management of neuroendocrine tumors. PET imaging with somatostatin analogs (SSAs) labeled with 68Ga or 64Cu is currently the gold standard in clinical practice.
Hannes Leupe, Stephen Ahenkorah, Jeroen Dekervel, Marcus Unterrainer, Eric Van Cutsem, Chris Verslype, Frederik Cleeren, Christophe M. Deroose   +7 more
openalex   +2 more sources

Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals. [PDF]

Cancers (Basel), 2022
Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology because these proteins are overexpressed on the cell membranes of different human malignancies, especially neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs)
Fani M, Mansi R, Nicolas GP, Wild D.
europepmc   +2 more sources

Meningiomas and Somatostatin Analogs: A Systematic Scoping Review on Current Insights and Future Perspectives. [PDF]

Int J Mol Sci, 2023
Tollefsen SE, Solheim O, Mjønes P, Torp SH.   +3 more
europepmc   +3 more sources

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation [PDF]

J Endocr Soc, 2021
Stelmachowska-Banas M, Czajka-Oraniec I, Tomasik A, Zgliczynski W.   +3 more
europepmc   +3 more sources

Somatostatin Analogs in Clinical Practice: a Review. [PDF]

Int J Mol Sci, 2020
Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of somatotropinomas, thyrotropinomas, and functioning and non-functioning gastroenteropancreatic neuroendocrine tumors.
Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C.   +2 more
europepmc   +2 more sources

Synthetic somatostatin analogs beyond cancer. [PDF]

Pituitary
Barabutis N, Siejka A.
europepmc   +3 more sources

The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med, 2022
Panzuto F, Ricci C, Rinzivillo M, Magi L, Marasco M, Lamberti G, Casadei R, Campana D.   +7 more
europepmc   +3 more sources

Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. [PDF]

Oncologist, 2020
BACKGROUND Somatostatin analogs (SSAs) are the mainstay of neuroendocrine tumor (NET) treatment. Biliary stone disease is reported as a common side effect of SSAs, with a frequency ranging from 10% to 63%.
Brighi N, Panzuto F, Modica R, Gelsomino F, Albertelli M, Pusceddu S, Massironi S, Lamberti G, Rinzivillo M, Faggiano A, Spallanzani A, Ferone D, Prinzi N, Rossi RE, Annibale B, Colao AM, Campana D.   +16 more
europepmc   +2 more sources